Investigation underway for securities fraud lawsuit against Replimune Group (REPL)

Replimune Group, Inc., a clinical-stage biotechnology company based in Woburn, Massachusetts, is currently under investigation by law firm Shamis & Gentile P.A. for potential securities fraud claims. Investors who suffered losses after holding Replimune Group securities may be able to join this investigation and seek compensation.

Replimune Group focuses on developing oncolytic immunotherapies using a herpes simplex virus (HSV-1) backbone to treat cancer. Its lead asset, RP1, was created for treatment in combination with nivolumab for advanced melanoma and other solid tumors. The success of RP1 is crucial to Replimune’s business model, as it was the company’s sole late-stage asset during the relevant period.

The investigation is centered around allegations that Replimune, along with certain officers and directors, may have provided misleading information or omitted crucial details regarding the regulatory status and commercial potential of RP1. Despite repeatedly assuring investors in press releases and filings that the Biologics License Application (BLA) for RP1 was progressing smoothly and that the FDA had not identified any issues, Replimune’s disclosures on July 22, 2025, revealed that the FDA had issued a Complete Response Letter (CRL) rejecting the BLA. The FDA stated that the pivotal IGNYTE study did not provide substantial evidence of effectiveness.

Subsequent disclosures on September 18, 2025, following a follow-up “Type A” meeting with the FDA, indicated that a path forward under the accelerated approval pathway had not been determined. These revelations appeared to contradict earlier public statements and had a significant impact on the company’s stock price, resulting in notable declines.

Investors and analysts believe that these events raise concerns about Replimune’s internal controls, risk management procedures, and the accuracy of its public disclosures. A timeline of key events includes a positive pre-BLA meeting on September 9, 2024, the FDA Breakthrough Therapy designation for RP1 on November 21, 2024, and the FDA accepting the BLA with Priority Review on January 21, 2025.

On May 22, 2025, Replimune indicated readiness for regulatory approval, further fueling expectations. However, the issuance of the CRL on July 22, 2025, marked a significant setback, leading to a sharp drop in the company’s stock price. The subsequent disclosure on September 18, 2025, about the uncertainties in the accelerated approval pathway also had a negative impact on shareholders.

As the investigation into potential breaches of fiduciary duty and other misconduct at Replimune Group continues, stockholders who experienced losses post the July and September 2025 disclosures may have rights to pursue legal action. Seeking company records under Delaware’s Section 220 and exploring derivative actions may be viable courses of action for affected shareholders. To safeguard their rights, investors are encouraged to act promptly, as there are time-sensitive deadlines and procedural requirements in such cases.